ISET 24: LIFE-BTK in 2024

Published: 09 Feb 2024

  • Views:

    Views Icon 170
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

ISET 24 - We are joined by investigator, Prof Ramon Varcoe (Prince of Wales Hospital, AU) to discuss the LIFE-BTK Study (NCT04227899) in consideration of the recently published position statement on BTK endovascular revascularization.

Sponsored by Abbott, LIFE-BTK is a pivotal randomized controlled trial evaluating the safety and efficacy of the everolimus-eluting Esprit BTK System for treating critical limb ischemia (CLI). 255 participants were enrolled in the trial and were randomized 2:1 to receive either the Esprit Device or balloon angioplasty.

In this interview, Prof Varcoe outlines the findings from a subgroup analysis of Rutherford class 4 or 5 LIFE-BTK patients, as well as JACC's paper, "Below-the-Knee Endovascular Revascularization: A Position Statement".

Interview Questions:

  1. What are the current treatment options for BTK disease, and what are the unmet needs in this area?
  2. What were the key findings from the subgroup analysis?
  3. How do the findings of LIFE-BTK figure into the recently published position statement on BTK Endovascular revascularization?
  4. What are some of the potentials of this technology, in terms of changing practice?
  5. What are the next steps?

Recorded remotely from Sydney, 2024.

Editor: Jordan Rance
Video Specialist: Oliver Miles

Support: This is an independent interview conducted by Radcliffe Cardiology.


You must be to comment. If you are not registered, you can register here.